Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Iqvia Holdings Inc.
  6. Summary
    IQV   US46266C1053

IQVIA HOLDINGS INC.

(IQV)
  Report
Real-time Estimate Cboe BZX  -  01:05 2022-07-06 pm EDT
215.97 USD   +0.31%
07:31aIQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Services
BU
07/04Knight Therapeutics Announces Relaunch of AKYNZEO in Brazil
MT
06/30Pharmaxis Names New Chief Medical Officer
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
214.11(c) 216.99(c) 215.05(c) 215.31(c) 215.555 Last
1 143 234 1 811 578 856 325 775 334 223 652 Volume
+0.90% +1.35% -0.89% +0.12% +0.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 14 619 M - -
Net income 2022 1 300 M - -
Net Debt 2022 10 349 M - -
P/E ratio 2022 31,9x
Yield 2022 -
Sales 2023 16 093 M - -
Net income 2023 1 579 M - -
Net Debt 2023 9 702 M - -
P/E ratio 2023 25,7x
Yield 2023 -
Capitalization 40 754 M 40 754 M -
EV / Sales 2022 3,50x
EV / Sales 2023 3,14x
Nbr of Employees 82 000
Free-Float 73,3%
More Financials
Company
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical... 
Read more
More about the company
Ratings of Iqvia Holdings Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about IQVIA HOLDINGS INC.
07:31aIQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Service..
BU
07/04Knight Therapeutics Announces Relaunch of AKYNZEO in Brazil
MT
06/30Pharmaxis Names New Chief Medical Officer
MT
06/24IQVIA HOLDINGS INC.(NYSE : IQV) dropped from Russell Midcap Value Index
CI
06/24IQVIA HOLDINGS INC.(NYSE : IQV) dropped from Russell 1000 Value Index
CI
06/24IQVIA HOLDINGS INC.(NYSE : IQV) dropped from Russell 3000E Value Index
CI
06/24IQVIA HOLDINGS INC.(NYSE : IQV) dropped from Russell 3000 Value Index
CI
06/16IQVIA HOLDINGS INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
06/10TRANSCRIPT : IQVIA Holdings Inc. Presents at 2022 Jefferies Global Healthcare Conference, ..
CI
06/07IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions
BU
06/07IQVIA Appoints Christina Mack as Chief Scientific Officer of Real World Solutions, Effe..
CI
06/06Pfizer to Invest $120 Million to Boost Covid-19 Pill Output
DJ
06/01Global Oncology R&D Surges While Cancer Care Disruptions Ease, Says IQVIA Institute for..
BU
05/25IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
BU
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
More news
News in other languages on IQVIA HOLDINGS INC.
06/07IQVIA nomme Christina Mack au poste de Chief Scientific Officer de Real World Solutions..
05/05TikoMed AB et IQVIA annoncent une collaboration stratégique pour le développement du pr..
04/29Les actions d'IQVIA Holdings augmentent en milieu de journée suite à la revalorisation ..
04/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent avant la cloche d..
04/27Le bénéfice ajusté et le chiffre d'affaires d'Iqvia progressent au premier trimestre ; ..
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Chart IQVIA HOLDINGS INC.
Duration : Period :
Iqvia Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 215,31 $
Average target price 262,39 $
Spread / Average Target 21,9%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Costa Panagos President-Research & Development Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-23.69%40 754
MODERNA, INC.-38.76%61 868
LONZA GROUP AG-30.46%40 540
SEAGEN INC.14.34%32 539
CELLTRION, INC.-7.58%19 261
ALNYLAM PHARMACEUTICALS, INC.-11.12%18 210